knowledge -WSS

knowledge

author：focus 2025-10-02 21:05:05 - browse：469

novavax photo illo — JUSTIN TALLIS/AFP via Getty Images

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hello, all. Damian here with an update on the plight of the other Covid-19 vaccine company, Wall Street’s latest GLP-1 trade, and the quest for a universal antivenom.

The need-to-know this morning

Ocular Therapeutics announced a shakeup of its senior management team and a $325 million private placement.
Amylyx Therapeutics said results from a closely followed Phase 3 study of its treatment for ALS could come before the start of the second quarter — earlier than previously expected.
Moderna earnings are here.

Novavax’s money is going in the wrong direction

The good news for Novavax is that it’s no longer facing a $700 million dispute with a global charity organization. The bad news is that settling that dispute will force the struggling company to pay out $400 million over the next five years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： ChatGPT in medicine: STAT answers readers' burning questions

hotspot

WSS

Cosmetics set for new safety regulation. Why the industry is on board

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

As demand for Covid shots wanes, Moderna seeks its next success

Cosmetics set for new safety regulation. Why the industry is on board

How one medical school became remarkably diverse

explore

knowledge

The need-to-know this morning

Novavax’s money is going in the wrong direction

entertainment

Tori Bowie and the unacceptable rates of Black maternal death

Medical records are filled with copy

How one medical school became remarkably diverse

BioMarin wins approval for gene therapy to treat hemophilia A

Psychedelics group wrestles with new pharma identity

Sanofi seeks simpler, safer CRISPR sickle cell cure

23andMe had bad news about my health. I wish a person had delivered it

How dance can help nurses traumatized by Covid

Medical records are filled with copy

Duchenne breakthrough therapy leaves behind pioneering families

knowledge

Malaria cases in Florida and Texas: Here’s what you need to know

Doctors find melanoma drugs effective against rare brain cancer

United colonoscopy coverage change 'may cost lives,' doctors say

Custom gene therapy hints at new path for rare disease treatments

How Medicaid coverage policies for immigrants impact new moms

Moonlake's readout produced a cash windfall. Risks remain

entertainment

leisure time

hotspot

hotspot